About the Authors

Sabrina J. Merat

Affiliation AIMM Therapeutics, Amsterdam, the Netherlands

Richard Molenkamp

Affiliation Department of Medical Microbiology, Section of Clinical Virology, Academic Medical Center, Amsterdam, the Netherlands

Koen Wagner

Affiliation AIMM Therapeutics, Amsterdam, the Netherlands

Sylvie M. Koekkoek

Affiliation Department of Medical Microbiology, Section of Clinical Virology, Academic Medical Center, Amsterdam, the Netherlands

Dorien van de Berg

Affiliation AIMM Therapeutics, Amsterdam, the Netherlands

Etsuko Yasuda

Affiliation AIMM Therapeutics, Amsterdam, the Netherlands

Martino Böhne

Affiliation AIMM Therapeutics, Amsterdam, the Netherlands

Yvonne B. Claassen

Affiliation AIMM Therapeutics, Amsterdam, the Netherlands

Bart P. Grady

Affiliation Department of Infectious Diseases Research and Prevention, Cluster of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands

Maria Prins

Affiliations Department of Infectious Diseases Research and Prevention, Cluster of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands, Department of infectious diseases, Academic Medical Center, Amsterdam, the Netherlands

Arjen Q. Bakker

Affiliation AIMM Therapeutics, Amsterdam, the Netherlands

Menno D. de Jong

Affiliation Department of Medical Microbiology, Section of Clinical Virology, Academic Medical Center, Amsterdam, the Netherlands

Hergen Spits

Affiliation AIMM Therapeutics, Amsterdam, the Netherlands

Janke Schinkel

Contributed equally to this work with: Janke Schinkel, Tim Beaumont

Affiliation Department of Medical Microbiology, Section of Clinical Virology, Academic Medical Center, Amsterdam, the Netherlands

Tim Beaumont

Contributed equally to this work with: Janke Schinkel, Tim Beaumont

tbeaumont@aimmtherapeutics.com

Affiliation AIMM Therapeutics, Amsterdam, the Netherlands

Competing Interests

We would like to disclose that S.J.M, K.W., D.V.B., E.Y., M.B., Y.B.C., A.Q.B., H.S. and T.B. are employees and S.J.M, K.W., E.Y., M.B., Y.B.C., A.Q.B., H.S. and T.B. are shareholders of AIMM Therapeutics. Materials have been generated by a for profit company, AIMM Therapeutics which makes research reagents available for academic research under conditions outlined in its Material Transfer Agreement (http://www.aimmtherapeutics.com/partnering/academic-collaboration/). This does not alter our adherence to PLOS ONE policies on sharing data and materials. Furthermore, S.J.M. received travel grants from the international symposium on Hepatitis C virus and related viruses. M.D.J. was a member of the AIMM scientific advisory board.

Author Contributions

Conceptualization: SJM RM HS JS TB. Funding acquisition: MDJ HS JS TB. Investigation: SJM KW DB EY MB YBC AQB. Methodology: SJM RM KW TB. Project administration: JS TB. Resources: RM KW SMK MP BPG MB YBC AQB HS MDJ JS. Supervision: SJM AQB RM JS TB. Validation: SJM KW DB SMK. Visualization: SJM KW. Writing – original draft: SJM RM KW AQB JS TB. Writing – review & editing: SJM RM MP BPG MDJ JS HS TB.